User login
Article Type
Changed
Wed, 04/16/2025 - 10:28
Display Headline
Brain Cancer: Epidemiology, TBI, and New Treatments
Click to view more from Cancer Data Trends 2025.
References
- Bihn JR, Cioffi G, Waite KA, et al. Brain tumors in United States military veterans.
Neuro Oncol. 2024;26(2):387-396. doi:10.1093/neuonc/noad182 - Stewart IJ, Howard JT, Poltavsky E, et al. Traumatic Brain Injury and Subsequent
Risk of Brain Cancer in US Veterans of the Iraq and Afghanistan Wars. JAMA Netw
Open. 2024;7(2):e2354588. doi:10.1001/jamanetworkopen.2023.54588 - DoD/USU Brain Tissue Repository. December 15, 2023. Accessed December 11,
2024. https://researchbraininjury.org/ - Munch TN, Gørtz S, Wohlfahrt J, Melbye M. The long-term risk of malignant
astrocytic tumors after structural brain injury--a nationwide cohort study. Neuro
Oncol. 2015;17(5):718-724. doi:10.1093/neuonc/nou312 - Strowd RE, Dunbar EM, Gan HK, et al. Practical guidance for telemedicine use in
neuro-oncology. Neurooncol Pract. 2022;9(2):91-104. doi:10.1093/nop/npac002 - Parikh DA, Rodgers TD, Passero VA, et al. Teleoncology in the Veterans Health
Administration: Models of Care and the Veteran Experience. Am Soc Clin Oncol Educ
Book. 2024;44(e100042. doi:10.1200/EDBK_100042 - Batool SM, Escobedo AK, Hsia T, et al. Clinical utility of a blood based assay for
the detection of IDH1.R132H-mutant gliomas. Nat Commun. 2024;15(1):7074.
doi:10.1038/s41467-024-51332-7 - Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al; INDIGO Trial Investigators.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med.
2023;389(7):589-601. doi:10.1056/NEJMoa2304194 - FDA. US Food and Drug Administration. FDA approves vorasidenib for Grade 2
astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.
Accessed December 11, 2024. https://www.fda.gov/drugs/resourcesinformation-
approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-oroligodendroglioma-
susceptible-idh1-or-idh2-mutation - NIH. National Cancer Institute. Tovorafenib Approved for Some Children with Low-
Grade Glioma. Accessed December 11, 2024. https://www.cancer.gov/news-events/
cancer-currents-blog/2024/pediatric-low-grade-glioma-tovorafenib-braf - The Veteran Population. Accessed December 11, 2024. https://www.va.gov/vetdata/
docs/surveysandstudies/vetpop.pdf - Miller AM, Szalontay L, Bouvier N, et al. Next-generation sequencing of
cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent
and young adult brain tumor patients. Neuro Oncol. 2022;24(10):1763-1772.
doi:10.1093/neuonc/noac035
Publications
Click to view more from Cancer Data Trends 2025.
Click to view more from Cancer Data Trends 2025.
References
- Bihn JR, Cioffi G, Waite KA, et al. Brain tumors in United States military veterans.
Neuro Oncol. 2024;26(2):387-396. doi:10.1093/neuonc/noad182 - Stewart IJ, Howard JT, Poltavsky E, et al. Traumatic Brain Injury and Subsequent
Risk of Brain Cancer in US Veterans of the Iraq and Afghanistan Wars. JAMA Netw
Open. 2024;7(2):e2354588. doi:10.1001/jamanetworkopen.2023.54588 - DoD/USU Brain Tissue Repository. December 15, 2023. Accessed December 11,
2024. https://researchbraininjury.org/ - Munch TN, Gørtz S, Wohlfahrt J, Melbye M. The long-term risk of malignant
astrocytic tumors after structural brain injury--a nationwide cohort study. Neuro
Oncol. 2015;17(5):718-724. doi:10.1093/neuonc/nou312 - Strowd RE, Dunbar EM, Gan HK, et al. Practical guidance for telemedicine use in
neuro-oncology. Neurooncol Pract. 2022;9(2):91-104. doi:10.1093/nop/npac002 - Parikh DA, Rodgers TD, Passero VA, et al. Teleoncology in the Veterans Health
Administration: Models of Care and the Veteran Experience. Am Soc Clin Oncol Educ
Book. 2024;44(e100042. doi:10.1200/EDBK_100042 - Batool SM, Escobedo AK, Hsia T, et al. Clinical utility of a blood based assay for
the detection of IDH1.R132H-mutant gliomas. Nat Commun. 2024;15(1):7074.
doi:10.1038/s41467-024-51332-7 - Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al; INDIGO Trial Investigators.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med.
2023;389(7):589-601. doi:10.1056/NEJMoa2304194 - FDA. US Food and Drug Administration. FDA approves vorasidenib for Grade 2
astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.
Accessed December 11, 2024. https://www.fda.gov/drugs/resourcesinformation-
approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-oroligodendroglioma-
susceptible-idh1-or-idh2-mutation - NIH. National Cancer Institute. Tovorafenib Approved for Some Children with Low-
Grade Glioma. Accessed December 11, 2024. https://www.cancer.gov/news-events/
cancer-currents-blog/2024/pediatric-low-grade-glioma-tovorafenib-braf - The Veteran Population. Accessed December 11, 2024. https://www.va.gov/vetdata/
docs/surveysandstudies/vetpop.pdf - Miller AM, Szalontay L, Bouvier N, et al. Next-generation sequencing of
cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent
and young adult brain tumor patients. Neuro Oncol. 2022;24(10):1763-1772.
doi:10.1093/neuonc/noac035
References
- Bihn JR, Cioffi G, Waite KA, et al. Brain tumors in United States military veterans.
Neuro Oncol. 2024;26(2):387-396. doi:10.1093/neuonc/noad182 - Stewart IJ, Howard JT, Poltavsky E, et al. Traumatic Brain Injury and Subsequent
Risk of Brain Cancer in US Veterans of the Iraq and Afghanistan Wars. JAMA Netw
Open. 2024;7(2):e2354588. doi:10.1001/jamanetworkopen.2023.54588 - DoD/USU Brain Tissue Repository. December 15, 2023. Accessed December 11,
2024. https://researchbraininjury.org/ - Munch TN, Gørtz S, Wohlfahrt J, Melbye M. The long-term risk of malignant
astrocytic tumors after structural brain injury--a nationwide cohort study. Neuro
Oncol. 2015;17(5):718-724. doi:10.1093/neuonc/nou312 - Strowd RE, Dunbar EM, Gan HK, et al. Practical guidance for telemedicine use in
neuro-oncology. Neurooncol Pract. 2022;9(2):91-104. doi:10.1093/nop/npac002 - Parikh DA, Rodgers TD, Passero VA, et al. Teleoncology in the Veterans Health
Administration: Models of Care and the Veteran Experience. Am Soc Clin Oncol Educ
Book. 2024;44(e100042. doi:10.1200/EDBK_100042 - Batool SM, Escobedo AK, Hsia T, et al. Clinical utility of a blood based assay for
the detection of IDH1.R132H-mutant gliomas. Nat Commun. 2024;15(1):7074.
doi:10.1038/s41467-024-51332-7 - Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al; INDIGO Trial Investigators.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med.
2023;389(7):589-601. doi:10.1056/NEJMoa2304194 - FDA. US Food and Drug Administration. FDA approves vorasidenib for Grade 2
astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.
Accessed December 11, 2024. https://www.fda.gov/drugs/resourcesinformation-
approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-oroligodendroglioma-
susceptible-idh1-or-idh2-mutation - NIH. National Cancer Institute. Tovorafenib Approved for Some Children with Low-
Grade Glioma. Accessed December 11, 2024. https://www.cancer.gov/news-events/
cancer-currents-blog/2024/pediatric-low-grade-glioma-tovorafenib-braf - The Veteran Population. Accessed December 11, 2024. https://www.va.gov/vetdata/
docs/surveysandstudies/vetpop.pdf - Miller AM, Szalontay L, Bouvier N, et al. Next-generation sequencing of
cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent
and young adult brain tumor patients. Neuro Oncol. 2022;24(10):1763-1772.
doi:10.1093/neuonc/noac035
Publications
Publications
Article Type
Display Headline
Brain Cancer: Epidemiology, TBI, and New Treatments
Display Headline
Brain Cancer: Epidemiology, TBI, and New Treatments
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
SLIDESHOW
Consolidated Pubs: Do Not Show Source Publication Logo
Use ProPublica
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article